Regencell Bioscience (NASDAQ:RGC) Shares Gap Down – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares gapped down prior to trading on Tuesday . The stock had previously closed at $13.83, but opened at $13.11. Regencell Bioscience shares last traded at $13.50, with a volume of 20,165 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, November 5th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Up 0.8%

The stock’s fifty day moving average price is $15.55.

Institutional Trading of Regencell Bioscience

Large investors have recently added to or reduced their stakes in the stock. Greenfield Savings Bank bought a new position in Regencell Bioscience in the 2nd quarter worth $187,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Regencell Bioscience during the second quarter valued at about $222,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience in the second quarter worth about $768,000. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience in the second quarter worth about $1,701,000. Finally, Geode Capital Management LLC boosted its position in Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after acquiring an additional 384,250 shares in the last quarter. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.